SOURCE: Actinium Pharmaceuticals

Actinium Pharmaceuticals

March 31, 2016 07:00 ET

Actinium Further Strengthens Clinical Development Team With Hiring of Director of Clinical Operations

Industry Veteran With Significant Experience in Global Pharmaceutical Companies and Clinical Research Organizations Selected to Manage Clinical Operations

NEW YORK, NY--(Marketwired - March 31, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Jennifer Liberi to the position of Director, Clinical Operations. Jennifer will report to Felix Garzon, M.D., Ph.D., Actinium's Head of Clinical Development and Senior Vice President. Jennifer will be responsible for managing Actinium's clinical trials, which will include, amongst other responsibilities, the training and leading of clinical trial sites, external service providers and internal staff, managing clinical trial budgets, supervising activities at clinical trial sites and preparing clinical aspects of regulatory submissions for Iomab-B, Actimab-A and future clinical programs.

Felix Garzon, M.D., Ph.D., Actinium's Head of Clinical Development, Senior Vice President said, "Jennifer has acquired invaluable clinical operations experience and knowledge during her 15 years at global pharmaceutical companies and CROs that will have an immediate impact on our Iomab-B Phase 3 trial, Actimab-A Phase 2 trial and future clinical programs. I welcome Jennifer to Actinium and look forward to working with her in driving our clinical development efforts forward."

Jennifer joins Actinium from Noven where she served as Director, Clinical Operations. At Noven, Jennifer planned and managed Phase 1 - 4 clinical trials and ensured that budgets and timelines associated with these trials were adhered to. Her responsibilities at Noven also included the preparation and review of protocols, consent forms, case report forms and other clinical trial documentation. In addition, she selected and managed external service providers, screened and selected study investigators, trained and oversaw clinical trial sites and prepared clinical trial related sections of regulatory submissions. Prior to Noven, Jennifer spent 10 years working at global pharmaceutical companies in roles of increasing responsibility including Merck Research Laboratories as Clinical Project Manager, Novartis as Global Clinical Research Manager, Hoffman La-Roche as Country Study Manager and at Bristol-Myers Squibb as Clinical Site Manager. Jennifer began her career at CROs, first with Quintiles as Clinical Research Associated and then at PRA International. Jennifer obtained her Bachelor of Arts degree from Monmouth University.

Sandesh Seth, Actinium's Executive Chairman said, "Jennifer is a welcome addition to the Actinium team and her joining comes at an ideal time as our Iomab-B Phase 3 trial and Actimab-A Phase 2 trial are poised to begin in the near future. Having Jennifer's knowledge and experience to complement our already excellent team gives me great confidence in our ability to execute on our clinical strategy and meet the many significant milestones we have set for ourselves in the coming months."

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information